65 related articles for article (PubMed ID: 8769702)
1. Analysis and validation of prognostic factors for CML. German CML Study Group.
Hasford J; Ansari H; Pfirrmann M; Hehlmann R
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S49-54. PubMed ID: 8769702
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
3. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
Hasford J; Pfirrmann M; Shepherd P; Guilhot J; Hehlmann R; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Steegmann JL; Thaler J
Haematologica; 2005 Mar; 90(3):335-40. PubMed ID: 15749665
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.
Hasford J; Pfirrmann M; Hehlmann R; Baccarani M; Guilhot F; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Thaler J; Steegmann JL;
Semin Hematol; 2003 Jan; 40(1):4-12. PubMed ID: 12563607
[TBL] [Abstract][Full Text] [Related]
7. [Prognostication of chronic Ph+ myeloid leukemia using the PHCML.EXE computer program].
Berger J; Chrobák L; Voglová J; Steruská M
Vnitr Lek; 1992 Feb; 38(2):160-5. PubMed ID: 1595204
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
9. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.
Passweg JR; Walker I; Sobocinski KA; Klein JP; Horowitz MM; Giralt SA;
Br J Haematol; 2004 Jun; 125(5):613-20. PubMed ID: 15147377
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias.
Boiron JM; Cahn JY; Meloni G; Carlo-Stella C; Bandini G; Reman O; Milpied N; Apperley J; Reiffers J
Bone Marrow Transplant; 1999 Aug; 24(3):259-64. PubMed ID: 10455363
[TBL] [Abstract][Full Text] [Related]
12. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
13. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
[TBL] [Abstract][Full Text] [Related]
14. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
15. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
16. [Multivariate analysis of prognostic factors in Philadelphia chromosome-positive chronic granulocytic leukemia].
Hao C; Wang Y; Li Q; Liu B; Qian L
Zhonghua Xue Ye Xue Za Zhi; 2001 Jan; 22(1):5-8. PubMed ID: 11877041
[TBL] [Abstract][Full Text] [Related]
17. [Effect of interferon-alpha on the prognosis of bone marrow transplantation in chronic myeloid leukemia].
Xu L; Guo N; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2001 Nov; 22(11):589-91. PubMed ID: 11855148
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
Hehlmann R; Heimpel H; Griesshammer M; Kolb HJ; Heinze B; Hossfeld DK; Wickramanayake PD; Essers U; Thiele J; Georgii A
Leukemia; 1992; 6 Suppl 3():110S-114S. PubMed ID: 1602805
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience.
Pigneux A; Faberes C; Boiron JM; Mahon FX; Cony-Makhoul P; Agape P; Lounici A; Bernard P; Bilhou-Nabera C; Bouzgarrou R; Marit G; Reiffers J
Bone Marrow Transplant; 1999 Aug; 24(3):265-70. PubMed ID: 10455364
[TBL] [Abstract][Full Text] [Related]
20. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
De Souza CA; Vigorito AC; Ruiz MA; Nucci M; Dulley FL; Funcke V; Tabak D; Azevedo AM; Byington R; Macedo MC; Saboya R; Penteado Aranha FJ; Oliveira GB; Zulli R; Martins Miranda EC; Azevedo WM; Lodi FM; Voltarelli JC; Simões BP; Colturato V; De Souza MP; Silla L; Bittencourt H; Piron-Ruiz L; Maiolino A; Gratwohl A; Pasquini R
Haematologica; 2005 Feb; 90(2):232-7. PubMed ID: 15710577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
